Since p53 has also been shown to directly repress the oncogenic miR-17-92a cluster (comprising miR-17, miR-18a, miR-20a, miR-19a, miR-19b and miR-92a) through binding the TATA box of the miR-17-92 promoters [19], we hypothesized that, via a p53-depedent mechanism, iASPP may promote cisplatin resistance by inducting this cluster, which was shown to enhance chemoresistance in mantle cell lymphoma [22]. This evidence concerns the gene TP53 and mantle cell lymphoma.